McLaughlin Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
McLaughlin Asset Management's BMY Position: Q2 2026 in Review
McLaughlin Asset Management increased its Bristol-Myers Squibb (BMY) stake by 11% in Q2 2026, buying an estimated $42.3K and bringing the position to 7,176 shares worth $413K. The position accounts for 0.28% of the portfolio, ranked #79.
McLaughlin Asset Management first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. 2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- McLaughlin Asset Management held 7,176 shares of Bristol-Myers Squibb worth $413K as of Q2 2026.
- McLaughlin Asset Management bought 736 Bristol-Myers Squibb shares in Q2 2026, an estimated $42.3K.
- Bristol-Myers Squibb made up 0.28% of McLaughlin Asset Management's portfolio in Q2 2026, its #79 holding.
- McLaughlin Asset Management first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
- 2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on McLaughlin Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.